Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hmmmm, maybe they will come out with details within the next couple of hours
I bought some at the end of day. Judging by how it traded prob not. But the pr said he was going to buy it out so well see.
Makes one wonder if this deal will go through.. I for one, hope it does!
Yes. Sounds like its a done deal right for 3 a share. Even from here that's a double.
This is interesting but I'm not convinced there will in fact be a buyout. The arb spread which is well above 40% and annualized as a comparable risk measure at an unheard of %480 reflects that unlikelihood.
Still worth watching but I wouldn't buy.
If in fact the "delisting details" which are supposed to follow shortly included language that suggests a real tender offer is in the offing, you should see the arbitrage spread shrink with the price approaching the buyout price mentioned. A timeline would be nice.
Wish this stock was optionable because I would cleanup either way.
This is what I don't understand
The Company also announced its intent to accept a "going private" proposal by Mr. Hong Yu, and cease its public company status. "In view of market bias towards Chinese companies listed in U.S. stock exchange and our past stock performance, I hereby make an offer to purchase TBET stocks not owned by me for $3.00 per share in cash,"said Mr. Hong Yu, "delisting details will be announced shortly".
$TBET - fyi...careful here imo..might be legit buyout still but risky...
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_T/threadview?m=tm&bn=122671&tid=69&mid=69&tof=2&frt=2
He only offered the company for $3, they did not find a buyer lol.. whats to be confused?
Agreed NSDQ continues to just sell more and more at 2.00
SOLIDDDDD thanks for the mention!
I'm really confused why is this not going to $3.00.
Profit takers. It will be back up soon.
if offering to buy out at 3 then why does this have a hard time getting over $2.05?
they are talking about allegations they mentioned in the PR - "In recent days, we noticed that a website mentioned about auctioning our operating entity's assets. These were untrue and incorrect announcements. Our company is in normal business operation. We're conducting our investigation on this mistaken report, and will keep our investors informed on the investigation result," said Mr. Hong Yu, CEO and Chairman of Tibet Pharmaceuticals
Nothing to watch, glad to get out on the TBET gap this morning...
g!!! Hammy loaded this Friday. We hit a winner!!!!!!
thats why they are going private dude. Because of all the nasty hit pieces on Chinese companies for the past year.
Tibet Pharm Conducting Investigation About Alleged Report
Last update: 2/27/2012 8:06:03 AM
(MORE TO FOLLOW) Dow Jones Newswires (212-416-2400)
February 27, 2012 08:06 ET (13:06 GMT)
ibet Pharmaceuticals, Inc. Announces Intent to Go Private
PR NewswirePress Release: Tibet Pharmaceuticals, Inc. – 24 minutes ago
NEW YORK, Feb. 27, 2012 /PRNewswire-Asia/ -- Tibet Pharmaceuticals, Inc. (NASDAQ: TBET - News), an emerging specialty pharmaceutical company engaged in the development, manufacturing and marketing of traditional Tibetan medicine in China, today announced that,
"In recent days, we noticed that a website mentioned about auctioning our operating entity's assets. These were untrue and incorrect announcements. Our company is in normal business operation. We're conducting our investigation on this mistaken report, and will keep our investors informed on the investigation result," said Mr. Hong Yu, CEO and Chairman of Tibet Pharmaceuticals. "The Company will take all necessary legal measures to defend itself against any untrue reports and to protect the interests of shareholders."
The Company also announced its intent to accept a "going private" proposal by Mr. Hong Yu, and cease its public company status. "In view of market bias towards Chinese companies listed in U.S. stock exchange and our past stock performance, I hereby make an offer to purchase TBET stocks not owned by me for $3.00 per share in cash,"said Mr. Hong Yu, "delisting details will be announced shortly".
Tibet Pharmaceuticals expects to continue to grow in China's fragmented pharmaceutical and traditional Tibetan medicine industries. The company is committed to establishing itself as a leading manufacturer and distributor of Tibetan medicine in China and believes that additional distribution channels will help enhance its completive advantages in the industry.
It's a scam!!!! Wires reporting investigation by TBET which followed the offer!!!!!
TBET $1.65 trading pre-market
largest volume day ever for this stock on Friday.....
KEEP A CLOSE EYE ON TBET THIS WEEK!!!!!!!!!!!!!
i think this is a winner and peeps are just beginning to notice it. nice to see you over here!
Tibet Pharmaceuticals Signs Letter of Intent to Cooperate With Anhui Taihe Pharmaceutical Group
Strategic Cooperation Anticipated to Extend Tibet Pharmaceuticals' Distribution Network in China
MarketwirePress Release: Tibet Pharmaceuticals, Inc. – Tue, Jan 31, 2012 4:05 PM EST
SHANGRI-LA COUNTY, CHINA--(Marketwire -01/31/12)- Tibet Pharmaceuticals, Inc. (NASDAQ: TBET - News), an emerging specialty pharmaceutical company engaged in the development, manufacturing and marketing of traditional Tibetan medicine in China, today announced that it has signed a Letter of Intent ("LOI") to cooperate with Anhui Taihe Pharmaceutical Group Co., Ltd. ("Anhui Taihe Pharmaceutical Group"), a wholesale pharmaceutical distribution company based in Anhui province with a network across 16 provinces and municipalities in China.
"The management team at Tibet Pharmaceuticals is extremely pleased to announce the signing of our LOI with Anhui Taihe Pharmaceutical Group," said Hong Yu, CEO and Chairman of Tibet Pharmaceuticals. "We expect the proposed strategic cooperation agreement to increase our line of Tibetan pharmaceutical products' reach and contribute to our expansion in China."
Established in 1995, Anhui Taihe Pharmaceutical Group distributes over 3,000 pharmaceutical products, including a wide variety of prescription and over-the-counter medicines. Anhui Taihe Pharmaceutical Group is fully GMP certified in China. Its wholesale distribution network covers 16 of China's 23 provinces, all 4 municipalities and numerous autonomous regions, with its main hub of operations centrally located in China's Anhui province. Tibet Pharmaceuticals believes that Anhui Taihe Pharmaceutical Groups' annual revenues are approximately $200 million USD.
Mr. Yu concluded, "We believe that relationships such as our cooperation with Anhui Taihe Pharmaceutical Group will provide additional avenues to sell our products and access new customers throughout China's growing pharmaceutical industry."
Tibet Pharmaceuticals expects to continue to grow in China's fragmented pharmaceutical and traditional Tibetan medicine industries. The company is committed to establishing itself as a leading manufacturer and distributor of Tibetan medicine in China and believes that additional distribution channels will help enhance its completive advantages in the industry.
NASDAQ: TBET (.72) Why this is MAJORLY undervalued:
Tibet Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Tibetan medicines.
http://www.tibetpharmaceuticals.com/
$26 Million CASH ON HAND
($1.75 per share)
Book Value per share: $3.18
$34 Million in Revenues
31% profit margin
Market Cap: $11 Million
http://finance.yahoo.com/q/ks?s=TBET+Key+Statistics
The stock IPO'd around 4.50 in April 2011 and since then has declined on very little volume. The overall lack of interest in Chinese companies for the past year has contributed greatly to the decline as investors have been weary of the accounting issues by several other Chinese companies.
TBET, however, has a strong balance sheet and based on this past Friday Feb. 24th's volume - an all time high for volume - may have just finally peaked the interest of investors.
http://finance.yahoo.com/news/Nasdaq-stocks-posting-largest-apf-121919750.html?x=0
Take a look at the chart here: http://stockcharts.com/c-sc/sc?s=TBET&p=D&yr=1&mn=0&dy=0&i=t83597123101&r=3473
The company has several drugs in development including a diabetes drug in Phase III as well as an impotence drug:
Shengke I that is in Phase III clinical testing for treating type II diabetes; Shengke II, which is in Phase II clinical testing for treating impotence and premature ejaculation, prostrate disease, and memory loss; Jiuzan pill that is in Phase II clinical testing for the treatment of chronic gastroenteritis and peptic ulcers; and Antai pill, a pre-clinical stage product for treating hepatitis B.
http://finance.yahoo.com/q/pr?s=TBET+Profile
Based on the strong financial position of the company, its strong drug pipeline, and the very low price per share, TBET could present investors with an excellent opportunity to see some major gains.
i think next week will be solid here. lots of new investors jumped on board this train - including myself!
largest volume day EVER!!!
TBET i am accumulating a position now....
TBET on the move!!!!!!!!!!!!!!!!
fundamentals are strong here... im looking to build a position here shortly... i see a strong rebound in the near future here.
stock looks like it is at a bottom...
this one looks interesting!
Tibet Pharmaceuticals Announces Appointment of Sherb & Co., LLP as New Independent Auditor
Sherb & Co. to Commence its Work Immediately with the Review of the Company's Upcoming Q3 2011 Financial Statements
Press Release Source: Tibet Pharmaceuticals, Inc. On Tuesday October 18, 2011, 9:01 am EDT
SHANGRI-LA COUNTY, China, Oct. 18, 2011 /PRNewswire/ -- Tibet Pharmaceuticals, Inc. (NASDAQ:TBET - News), an emerging specialty pharmaceutical company engaged in the development, manufacturing and marketing of traditional Tibetan medicine in China, announced today that it has engaged Sherb & Co., LLP ("Sherb & Co.") as its new independent auditor. Sherb & Co. will commence its work immediately with the review of the Company's third quarter financial statements, which are to be included in the Company's upcoming form 10-Q.
The decision to engage Sherb & Co. as the Company's independent registered public accounting firm was approved by the Audit Committee of the Company's Board of Directors. Formal notification detailing this action was filed in a Form 8-K with the SEC. Sherb & Co. is an SEC audit firm based in New York City that is registered with the Public Company Accounting Oversight Board (PCAOB) and provides a range of comprehensive accounting and auditing services to public companies in a full spectrum of industries. Sherb & Co. maintains offices in New York City; Boca Raton, Florida; as well as Beijing, China.
Mr. Hong Yu, CEO and Chairman of Tibet Pharmaceuticals stated, "After an extensive search process, we are pleased to engage Sherb & Co. as our new auditor. The firm has wide experience working with U.S.-listed Chinese companies, as well as handling SEC rules and regulations for more than 90 publicly traded enterprises. We believe Sherb & Co. offers Tibet Pharmaceuticals and our shareholders a strong combination of high quality services and extensive experience, and we look forward to working with them in the future."
The Company did not have any disagreements with its previous auditor, Acquavella, Chiarelli, Shuster, Berkower & Co., LLP, on any matter of accounting principles or practices, financial statement disclosures or auditing scope or procedure.
About Tibet Pharmaceuticals, Inc.
Based in Shangri-La County, Yunnan Province, China, Tibet Pharmaceuticals, Inc. (NASDAQ:TBET - News) is a rapidly growing specialty pharmaceutical company engaged in the research, development, manufacturing and marketing of modernized traditional Tibetan medicines in China. With over 190 employees and nation-wide distributors, the company develops both prescription and over-the-counter traditional Tibetan medicines that promote health in human respiratory, digestive, urinary and reproductive systems. Tibet Pharmaceuticals' products are sold throughout China, with a majority of sales concentrated in the southern provinces, most notably Yunnan Province, where the company's 52,000 sq. ft. GMP-certified manufacturing facilities are located. The access to key raw materials, not generally available outside the province, provides a significant advantage for Tibet Pharmaceuticals.
For comprehensive investor relations material, including fact sheets, research reports, presentations and video, please follow the appropriate link: Research Report, Investor Portal and Overview Video.
For more information on Tibet Pharmaceuticals, please visit:
www.tibetpharmaceuticals.com
TBET: T12 Halt:
http://nasdaqtrader.com/Trader.aspx?id=TradeHalts
Murphy Analytics Issues Updated Research Report on Tibet Pharmaceuticals
New Report Outlines Recent Developments, States that Tibet is Trading at Less than Cash Value
Press Release Source: Tibet Pharmaceuticals, Inc. On Monday August 22, 2011, 8:15 am EDT
SHANGRI-LA COUNTY, China, Aug. 22, 2011 /PRNewswire/ -- Tibet Pharmaceuticals, Inc. (NASDAQ:TBET - News), an emerging specialty pharmaceutical company engaged in the development, manufacturing and marketing of traditional Tibetan medicine in China, today announced the release of an in-depth research report update by Patrick Murphy, CFA, principal of fee-based, third-party research firm Murphy Analytics.
In his report, Mr. Murphy discusses Tibet Pharmaceuticals' business and current portfolio of five traditional Tibetan medicine products, outlines recent developments and states that Tibet is trading at less than cash value.
"Through our strong growth initiatives and portfolio of five SFDA-approved medicines, Tibet Pharmaceuticals is addressing the increasing demand for pharmaceutical and healthcare products in China," said Hong Yu, CEO and Chairman of Tibet Pharmaceuticals. "This research report update provides investors with an in-depth analysis of Tibet's particular strengths in the Traditional Chinese Medicine, or TCM, market in China and delivers a comprehensive overview of our recently reported revenue and earnings as we seek to continue to drive growth in 2011."
This research report update provides investors with a current analysis of the growth of the Chinese pharmaceutical market, and delivers a comprehensive overview of Tibet Pharmaceuticals' recently-reported revenue and earnings. Murphy Analytics also explains that despite Tibet Pharmaceuticals' revenue growth, its current valuation multiple is lower than many of its peers.
In his updated report, Mr. Murphy states, "Various benchmark indices, with varying degrees of relevance for TBET operations, are trading at price / earnings multiples ranging from 12.6x to 20.5x. A smaller sampling of publicly traded stocks generally operating in the Chinese healthcare / pharmaceutical sector is trading at an average P/E multiple of 5.3x, while TBET is trading at less than half the multiple for this sampling and generally in line with peers that are struggling rather than reporting earnings and revenue growth like TBET."
"At a recent market cap of $26.7 million, TBET is trading at less than the $29.5 in cash and cash equivalents reported as of 6/30/11," concludes Mr. Murphy.
The complete report, which was commissioned by Tibet Pharmaceuticals, Inc., is available in Acrobat format, free of charge: http://www.murphyanalytics.com/uploads/TBET_Update.pdf
About Tibet Pharmaceuticals, Inc.
Based in Shangri-La County, Yunnan Province, China, Tibet Pharmaceuticals, Inc. (NASDAQ:TBET - News) is a rapidly growing specialty pharmaceutical company engaged in the research, development, manufacturing and marketing of modernized traditional Tibetan medicines in China. With over 190 employees and nation-wide distributors, the company develops both prescription and over-the-counter traditional Tibetan medicines that promote health in human respiratory, digestive, urinary and reproductive systems. Tibet Pharmaceuticals' products are sold throughout China, with a majority of sales concentrated in the southern provinces, most notably Yunnan Province, where the company's 52,000 sq. ft. GMP-certified manufacturing facilities are located. The access to key raw materials, not generally available outside the province, provides a significant advantage for Tibet Pharmaceuticals.
For comprehensive investor relations material, including fact sheets, research reports, presentations and video, please follow the appropriate link: Research Report, Investor Portal and Overview Video.
For more information on Tibet Pharmaceuticals, please visit: www.tibetpharmaceuticals.com
Information Regarding the Murphy Analytics Report
SEC Section 17(b) Disclosure: Murphy Analytics has been paid $3,000 by Tibet Pharmaceuticals, Inc. Although the Murphy Analytics report described herein was commissioned and paid for by Tibet Pharmaceuticals, Inc., the company notes that the report was generated independently by Mr. Murphy, and statements by Mr. Murphy are his own and not attributable to Tibet Pharmaceuticals, Inc. Readers are advised to review the report in its entirety, including the disclosures and disclaimers noted therein.
Forward-Looking Statements
This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. Specifically, references herein to contemplated growth in company revenues and/or earnings or expected company valuations are forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, changes in company valuations and investor perceptions of companies, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In particular, the company advises investors that the company commissioned the research report discussed in this press release. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
Financial Communications Contact:
Trilogy Capital Partners - Asia
Darren Minton, President
Toll-free: 800-592-6067
info@trilogy-capital.com
SURF, your a busy guy I can see with tracking alot of boards. Whats with the selloff here? Any input into any recent events? Looks to be at a bottom and watching for 2.00 break.
Tibet Pharmaceuticals Announces Availability of First Quarter 2011 Earnings Call Transcript
Management Team Discusses Tibet's Lead Products, Business Strategy and Recent Financial Performance
Press Release Source: Tibet Pharmaceuticals, Inc. On Friday May 20, 2011, 8:30 am EDT
SHANGRI-LA COUNTY, China, May 20, 2011 /PRNewswire/ -- Tibet Pharmaceuticals, Inc. (NASDAQ:TBET - News), an emerging specialty pharmaceutical company engaged in the development, manufacturing and marketing of traditional Tibetan medicine in China, today announced the availability of the transcript for its first quarter 2011 earnings conference call, held on May 17th.
During the conference call Taylor Guo, Tibet Pharmaceutical's Chief Executive Officer, stated, "With our modern 52,000 square-foot facility, and our unique location in the Qinghai-Tibet Plateau and our five SFDA approved medicines, Tibet Pharmaceuticals is committed to meeting the greater demand for Traditional Chinese Medicine."
"During the first quarter Tibet achieved the milestone event of becoming a NASDAQ listed company and raising $16.5 million in our Initial Public Offering," continued Mr. Guo. "As we move into the second quarter of 2011, we expect to further increase marketing and advertising for our growing portfolio of traditional Tibetan medicines, with a particular focus on organic growth and accretive acquisitions."
Throughout the conference call Tibet Pharmaceutical's CEO spoke about the company's portfolio of traditional Tibetan medicine products, its operations and production capacity and full details surrounding its revenue and earnings numbers for the fiscal first quarter ended March 31, 2011.
Interested parties are encouraged to read the full transcript of the conference call, available here: www.trilogy-capital.com/autoir/tbet_autoir.html
About Tibet Pharmaceuticals, Inc.
Based in Shangri-La County, Yunnan Province, China, Tibet Pharmaceuticals, Inc. (NASDAQ:TBET - News) is a rapidly growing specialty pharmaceutical company engaged in the research, development, manufacturing and marketing of modernized traditional Tibetan medicines in China. With over 190 employees and nation-wide distributors, the company develops both prescription and over-the-counter traditional Tibetan medicines that promote health in human respiratory, digestive, urinary and reproductive systems. Tibet Pharmaceuticals' products are sold throughout China, with a majority of sales concentrated in the southern provinces, most notably Yunnan Province, where the company's 52,000 sq. ft. GMP-certified manufacturing facilities are located. The access to key raw materials, not generally available outside the province, provides a significant advantage for Tibet Pharmaceuticals.
For comprehensive investor relations material, including fact sheets, research reports, presentations and video, please follow the appropriate link: Research Report, Investor Portal and Overview Video.
For more information on Tibet Pharmaceuticals, please visit:
www.tibetpharmaceuticals.com
Tibet Pharmaceuticals Reports Financial Results for First Quarter Ended March 31, 2011
Earnings Conference Call Scheduled for Tuesday, May 17 at 9:30 am Eastern
Press Release Source: Tibet Pharmaceuticals, Inc. On Monday May 16, 2011, 5:08 pm EDT
SHANGRI-LA COUNTY, China, May 16, 2011 /PRNewswire/ -- Tibet Pharmaceuticals, Inc. (NASDAQ:TBET - News), an emerging specialty pharmaceutical company engaged in the development, manufacturing and marketing of traditional Tibetan medicine in China, today reported its financial results for the first quarter ended March 31, 2011.
Summary of First Quarter Ended March 31, 2011 Financial Results:
Revenue of $8.2 million, an increase of 17% from $7.0 million in Q1 2010
Gross profit of $3.5 million compared to $3.5 million in Q1 2010
Net income of $2.6 million compared to $2.8 million in Q1 2010
Fully diluted EPS of $0.18
"Tibet Pharmaceuticals is pleased to report our financial results for the first quarter of 2011," said Taylor Guo, Chief Executive Officer at Tibet Pharmaceuticals. "We demonstrated a steady 17% increase in revenue in the first quarter of 2011, as well as maintaining net income margins upwards of 30%. Although our net income decreased slightly compared to the first quarter of 2010, this was due primarily to the rising cost of raw materials, and our management team believes this will begin to improve going forward as we initiate efforts to increase the prices of our products accordingly. Subsequent to the end of the first quarter, on May 1 we initiated our first price increase since becoming a public company and we believe this will have a positive impact on our margins going forward."
All of Tibet Pharmaceuticals' current products are offered and derived from Tibetan-based traditional medicines with natural herbs and minerals found in the high-latitude, low-temperature, and pollution-free environment of Qinghai-Tibet Plateau. Tibet Pharmaceuticals currently sells 5 prescription and over-the-counter Tibetan medicine products, with each having been approved by the State Food and Drug Administration of China, also known as the SFDA.
Tibet Pharmaceuticals expects to continue to grow in China's fragmented pharmaceutical and traditional Tibetan medicine industries. The company is committed to establishing itself as a leading manufacturer and distributor of Tibetan medicine in China.
Mr. Guo added, "Tibet Pharmaceuticals is looking to leverage its proceeds from its IPO earlier this year toward potential accretive acquisitions to help the company expand within the highly fragmented traditional Tibetan medicine industry. Tibet's management team has already identified several targets and looks forward to relaying more details over the coming weeks and months."
Highlights for the 2011 First Quarter:
Revenue was $8.2 million along with net income of $2.6 million, resulting in fully diluted EPS of $0.18 for the first quarter ended March 31, 2011.
Tibet Pharmaceuticals currently has 190 full-time employees and sells 5 prescription and over-the-counter Tibetan medicine products, each of which has been approved by the SFDA.
Revenues from Tibet Pharmaceuticals' biggest product sales contributor, its 25 Ingredients Mandrake Pill, increased 22% from $3.2 million in Q1 2010 to $3.9 million in Q1 2011.
Expansion of Tibet Pharmaceuticals' existing distributor network contributed to revenue growth during the first quarter ended March 31, 2011.
The company's first price increase since becoming a public company took place May 1, 2011 and is expected to improve margins and enhance net income going forward.
Going forward in fiscal 2011, Tibet Pharmaceuticals expects to increase its distribution network for its growing portfolio of traditional Tibetan medicines through various organic growth strategies, while also looking for opportunities for accretive acquisitions and licensing arrangements.
In China, traditional Tibetan medicine is not an alternative form of therapy but is used in the state-run hospitals alongside modern medicine. For its practitioners and advocates, traditional Tibetan medicine is seen as a safe and effective solution to diseases, having the advantage of causing fewer side effects than western medicine, due to the natural ingredients used. Traditional Tibetan medicine is also believed to promote long term wellness and vigor and many modern-day drugs have been developed from herbal sources.
Tibet Pharmaceuticals believes that it has benefited from the overall economic development in China in recent years and the increase in the number of elderly people in China, which together have resulted in increased expenditures on medicine in China, including traditional Tibetan medicine. With the improvement of living standards in China, the health care industry has grown substantially in recent years, which also stimulated the domestic demands for Tibetan medicine. As China's elder population grows, as well as the increased awareness and perception of the safety of traditional Tibetan medicine products, the market demand for traditional Tibetan medicine products is expected to continue to rise.
Earnings Conference Call Details:
Tibet Pharmaceuticals will host a conference call on Tuesday, May 17 at 9:30 am Eastern to discuss its financial results for the first quarter ended March 31, 2011.
The teleconference can be accessed by dialing 877-407-0778 when calling within the United States or 201-689-8565 when calling internationally. Please dial in 10 minutes prior to the beginning of the call. There will be a playback available until May 31, 2011. To listen to the playback dial 877-660-6853 when calling within the United States, or 201-612-7415 when calling internationally and use account number: 286, in conjunction with replay ID number: 372828.
The conference call will be simultaneously webcast and available on the company's website, www.tibetpharmaceuticals.com, under the "Events and Presentations" tab of the "Investors" section.
About Tibet Pharmaceuticals, Inc.
Based in Shangri-La County, Yunnan Province, China, Tibet Pharmaceuticals, Inc. (NASDAQ:TBET - News) is a rapidly growing specialty pharmaceutical company engaged in the research, development, manufacturing and marketing of modernized traditional Tibetan medicines in China. With over 190 employees and nation-wide distributors, the company develops both prescription and over-the-counter traditional Tibetan medicines that promote health in human respiratory, digestive, urinary and reproductive systems. Tibet Pharmaceuticals' products are sold throughout China, with a majority of sales concentrated in the southern provinces, most notably Yunnan Province, where the company's 52,000 sq. ft. GMP-certified manufacturing facilities are located. The access to key raw materials, not generally available outside the province, provides a significant advantage for Tibet Pharmaceuticals.
For comprehensive investor relations material, including fact sheets, research reports, presentations and video, please follow the appropriate link: Research Report, Investor Portal and Overview Video.
http://finance.yahoo.com/news/ARX01-and-ARX03-Clinical-prnews-3931863714.html?x=0&.v=1
Followers
|
20
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
210
|
Created
|
03/22/11
|
Type
|
Free
|
Moderators |
http://www.tibetpharmaceuticals.com/
http://www.tibetpharmaceuticals.com/investors.html
http://finance.yahoo.com/q/ks?s=TBET+Key+Statistics
Based in Shangri-La County, in Yunnan Province, China, Tibet Pharmaceuticals, Inc. (Nasdaq: TBET) is a growing and profitable specialty pharmaceutical company engaged in the research, development, manufacturing and marketing of modernized traditional Tibetan medicines.
All of its current products are offered and derived from Tibetan based traditional medicines and are manufactured by Tibet Pharmaceuticals using plant-based natural materials, particularly the herbs and minerals found in the high-latitude, low-temperature, and pollution-free environment of the Qinghai-Tibet Plateau. Tibet Pharmaceuticals sells five major prescription and over-the-counter Tibetan medicine products, each of which has certain medicinal functions and has demonstrated safety and efficacy in accordance with China's SFDA requirements.
Tibet Pharmaceuticals' objectives are to maintain and strengthen the position of its products in the Tibetan medicine healthcare segment in China. The company is expanding its distribution network to diversify and broaden its market penetration. Tibet Pharmaceuticals intends to further expand its reach by building or acquiring national or regional distribution points to drive additional growth of its existing and future products. Pursuing additional acquisitions and licensing opportunities is a significant component of Tibet Pharmaceuticals' growth strategy. Acquisition targets would be Tibetan pharmaceutical companies who have very competitive products, with strong efficacy.
Tibet Pharmaceuticals believes that it has benefited from the overall economic development in China in recent years and the increase in the number of elderly people in China, which together have resulted in increased expenditures on medicine in China, including traditional Tibetan medicine. The Chinese have long perceived and accepted traditional Tibetan medicine as a safe and effective solution to diseases, having the advantage of causing fewer side effects than western medicine, due to the natural ingredients used. With the improvement of living standards in China, the health care industry has grown substantially in recent years, which also stimulated the domestic demands for Tibetan medicine. As China's elder population grows, as well as the increased awareness and perception of the safety of traditional Tibetan medicine products, the market demand for traditional Tibetan medicine products is expected to keep growing.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |